Omnicell Q1 revenue climbs
The company has posted net loss of $670,000, compared to $979,000 for the same period last year. For the first quarter of 2011, Omnicell‘s loss from operations was
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).